<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03474536</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2017/35</org_study_id>
    <nct_id>NCT03474536</nct_id>
  </id_info>
  <brief_title>Quantitative Parameters of HLA-DQ Antibodies in Lung Transplantation</brief_title>
  <acronym>AFFIHLA-P</acronym>
  <official_title>Clinical Impact of Concentration and Affinity of HLA-DQ Antibodies in Lung Transplantation - AFFIHLA-P</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to compare the quantitative parameters of de novo anti-HLA DQ Donor Specific
      Antibodies (DSA), determined at the time of their discovery by surface plasmon resonance
      (SPR), between recipients that developed a Chronic Lung Allograft Dysfunction (CLAD) for the
      2 years following DSA apparition and those who did not. If concentration, kinetics and/or
      affinity parameters of anti-DQ DSA are associated with CLAD development, new, non-invasive
      prognostic biomarkers of humoral rejection in lung transplantation will be discovered .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After lung transplantation the production of de novo DSA directed against HLA-DQ molecules is
      associated with CLAD and graft loss. The most used assay for serum DSA detection is the
      Single Antigen Luminex® (SAG), which provides a semi-quantitative fluorescence value, the
      MFI, used as a surrogate of DSA &quot;strength&quot;. But MFI is not perfectly associated with CLAD
      development. We developed a method using SPR allowing the concentration, kinetics (ka, kd)
      and affinity parameters (KD) of anti-DQ DSA to be determined. These quantitative parameters
      could represent biomarkers finely associated with CLAD. The way this parameters evolve
      (stability, increase or decrease) with time could also impact on DSA pathogenicity. We will
      compare the quantitative parameters of de novo anti-HLA DQ DSA, determined at the time of
      their discovery, between recipients that developed a CLAD for the 2 years following DSA
      apparition, and those who did not. The association between quantitative parameters of DSA and
      graft loss, their evolution and its association with CLAD and graft loss, and their
      correlation with SAG MFI will be also evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CLAD development</measure>
    <time_frame>2 years</time_frame>
    <description>CLAD development within the 2 years following DSA apparition</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>raft loss up to 5 years following DSA apparition</measure>
    <time_frame>6 months, 1 year, 2 years, 5 years</time_frame>
    <description>Graft loss up to 5 years following DSA apparition, defined by re-transplantation or recipient's death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLAD development</measure>
    <time_frame>6 months</time_frame>
    <description>CLAD development 6 months following DSA apparition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLAD development</measure>
    <time_frame>1 year</time_frame>
    <description>CLAD development 1 year following DSA apparition</description>
  </secondary_outcome>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Lung Transplantation</condition>
  <condition>Antibody Mediated Rejection</condition>
  <condition>Chronic Lung Allograft Dysfunction</condition>
  <eligibility>
    <study_pop>
      <textblock>
        122 patients with lung transplantation at University Hospital of Bordeaux and 4 departments
        of lung transplantation from Paris (Marie Lannelongue, Foch, Bichat and HEGP hospitals
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years and older

          -  Patient transplanted between 01/01/2001 and 31/07/2016

          -  Patient with immunodominant anti-HLA DQ de novo DSA developed before 08/2016

          -  Patient for who sufficient remaining serum quantity is available in usual care biobank

          -  non-opposition of the patient

        Exclusion Criteria:

          -  preformed DSA at the transplantation;

          -  Non immunodominant DQ DSA ;

          -  Insufficient serum quantity in usual care biobank

          -  Inability to determine the date of DSA apparition at around one year

          -  opposition of the patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jonathan Visentin, MD, Ph.D</last_name>
    <phone>+33557 82 08 85</phone>
    <email>jonathan.visentin@chu-bordeaux.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Marie Lannelongue</name>
      <address>
        <city>Le Plessis-Robinson</city>
        <zip>92350</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Romain Guillemain, MD, Ph.D</last_name>
      <phone>+331 56 09 29 64</phone>
      <email>guillemain.hegp@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier Brugière, MD, PhD</last_name>
      <phone>+331 40 25 69 14</phone>
      <email>olivier.brugiere@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine Roux, MD</last_name>
      <phone>+331 46 25 21 94</phone>
      <email>a.roux@hopital-foch.org</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2018</study_first_submitted>
  <study_first_submitted_qc>March 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2018</study_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung transplantation</keyword>
  <keyword>HLA antibodies</keyword>
  <keyword>concentration</keyword>
  <keyword>affinity</keyword>
  <keyword>surface plasmon resonance</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

